May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Evorpacept Pairs Well With Anticancer Regimens Plus Chemotherapy to Elicit Responses in Solid Tumors
November 10th 2021The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.
Read More
Devimistat and Modified FOLFIRINOX Shows No Survival Benefit in Metastatic Pancreatic Cancer
October 28th 2021Efficacy observed with the combination of devimistat and modified FOLFIRINOX in patients with metastatic pancreatic cancer has lead to a negative result in the phase 3 AVENGER 500 clinical trial.
Read More
Adding Eryaspase to Chemotherapy Show No OS Benefit in Advanced Pancreatic Cancer
October 26th 2021Topline results show that the addition of eryaspase to chemotherapy does not prolong survival in the general advanced pancreatic cancer population, but there may be benefit for those treated with irinotecan.
Read More
Exploring MRI-Guided Adaptive Radiation to Treat Inoperable Pancreatic Cancer
October 6th 2021In an interview with Targeted Oncology™, Michael Chuong, MD explained of the validity of the MRI-guided radiation technique for use in patients with pancreatic cancer, how it compares with CT-guided radiation, and how a shift toward MRI-guided radiation may impact patients with pancreatic cancer in the future.
Read More
Benefits of MRI-Directed Ablative Radiotherapy in Pancreatic Cancer
September 16th 2021Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.
Watch
MRI-Guided Radiation Therapy: A Novel Treatment for Pancreatic Cancer
September 16th 2021Complete surgical removal of a pancreatic tumor is not possible for most patients. Chemotherapy and radiation therapy are typically recommended to slow tumor growth, but ultimately are not expected to be curative, writes Michael Chuong, MD.
Read More
Tislelizumab Metastatic ESCC BLA Now Under FDA Consideration for Approval
September 13th 2021The FDA has accepted the biologics license application for tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma in previously treated patients.
Read More
New Therapies Challenge SOC in Genitourinary Cancers
August 25th 2021In an interview with Targeted Oncology™, Guru Sonpavde, MD, discussed the safety and efficacy of fixed-dose durvalumab for UTC along with an overview of the ongoing CheckMate 274 trial, which evaluates nivolumab compared to placebo in this patient population.
Read More